Watch List: Xerox Corp (NYSE:XRX), NRG Energy Inc (NYSE:NRG), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

On Thursday, Shares of Xerox Corp (NYSE:XRX), subtract -2.55% and closed at $9.55 in the last trading session. The last trading range of the stock ranges between $9.52 and $9.74. The U.S. Department of Agriculture (USDA) has awarded Xerox (XRX) a 10-year, $110M contract for managed print services (MPS) across all USDA agencies. As part of the agreement, Xerox will install and support up to 16,000 Xerox ConnectKey®-facilitated printers and multifunction devices at more than 3,000 USDA sites around the globe.

USDA is working with Xerox to reduce costs while creating a print, copy, fax and scan environment with fewer but more powerful devices and a smaller environmental footprint. New tools – like ready-to-use apps built into the interface – facilitated by the Xerox ConnectKey technology will support migration to digital workflows and provide detailed analytics to reduce print volumes and paper consumption.

“According to Gartner, companies spend between one and three percent of their annual revenue on printing, and managed print services can assist reduce the expenditure by nearly 30 percent,” said Mike Zimmer, president, U.S. Large Enterprise Operations, Xerox. “With Xerox’s technology and services, the USDA can reduce spending while modernizing their operations, improving security and freeing up vital IT resources to support mission-critical programs.”

NRG Energy Inc (NYSE:NRG), jumped 1.17% and closed at $11.27 in the last trading session. The last trading range of the stock ranges between $10.86 and $11.34. The company’s Market capitalization is $3.56 Billion with the total outstanding Shares of 315.28million. NRG Energy, Inc. (NRG) plans to report its Third Quarter 2016 financial results on Friday, November 4, 2016. Administration will present the results during a conference call and webcast at 8:00 am Eastern.

NRG is the leading integrated power company in the U.S., built on the strength of the nation’s leading and most diverse competitive electric generation portfolio and leading retail electricity platform. A Fortune 200 company, NRG creates value through best in class operations, reliable and efficient electric generation, and a retail platform serving residential and commercial businesses. Working with electricity customers, large and small, we continually innovate, embrace and implement sustainable solutions for producing and managing energy. We aim to be pioneers in developing smarter energy choices and delivering exceptional service as our retail electricity providers serve almost 3 million residential and commercial customers throughout the country.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK), jumped 1.58% and closed at $5.13 in the last trading session. The last trading range of the stock ranges between $4.91 and $5.16. During the 52-week trading session the minimum price at which share price traded, registered at $4.39 and reached to max level of $10.85. Merrimack Pharmaceuticals, Inc. (MACK) recently declared final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin, which represents a new standard of care for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) following treatment with gemcitabine-based therapy. The final NAPOLI-1 results were presented in a poster negotiation session and a separate analysis of NAPOLI-1 safety-over-time data was presented in a poster session at the European Society for Medical Oncology 2016 Congress in Copenhagen.

“The final results of the NAPOLI-1 study provide a high level of clinical evidence establishing the ONIVYDE regimen as a meaningful treatment option for patients with metastatic pancreatic cancer,” said Prof. Li-Tzong Chen, M.D., Ph.D., corresponding author, Investigator on the NAPOLI-1 trial and Director, National Institute of Cancer Research, National Health Research Institutes in Tainan, Taiwan. “Pancreatic cancer is a devastating disease with a poor prognosis. In a patient population with few treatment options, the ONIVYDE regimen provides an opportunity for extended overall survival while maintaining baseline quality-of-life and represents a new standard of care. We thank all of the patients, caregivers and investigators who take partd in this pivotal study.”

Leave a Reply

Your email address will not be published. Required fields are marked *